Injectable HIV Treatment Outperforms Daily Pills in Landmark Trial

The CROWN trial demonstrated that a two-monthly injection combining cabotegravir and rilpivirine achieved better viral suppression than traditional daily oral antiretroviral therapy in people with HIV and detectable virus loads. This is the first major randomized study to test direct initiation of the long-acting regimen without requiring a preceding period of oral medication-induced viral suppression. ViiV Healthcare intends to present complete findings to regulatory authorities and at scientific conferences.

The CROWN trial represents a significant shift in HIV treatment strategy by testing whether patients could begin a long-acting injectable regimen immediately, rather than first achieving viral control through traditional daily pills. The two-drug combination—cabotegravir and rilpivirine—demonstrated superior results at the six-month mark compared to conventional oral antiretroviral therapy in participants whose virus remained active at enrollment.

This approach differs from previous injectable HIV studies, which typically required patients to first suppress their virus with oral medications before transitioning to injections. The trial's success in the more challenging population of treatment-naive individuals with detectable viral loads could expand treatment options for people newly diagnosed or those experiencing barriers to daily pill adherence.